<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784613</url>
  </required_header>
  <id_info>
    <org_study_id>SDSM-2015-02</org_study_id>
    <nct_id>NCT02784613</nct_id>
  </id_info>
  <brief_title>Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA</brief_title>
  <official_title>Open-Label Pilot Prospective Vulvoscopy Photography Study of Visible Changes in the Vulva, Vestibule, Vagina Pre/Post 20 Weeks of Daily Administration 60 Mg Ospemifene in Post-Menopausal Women With Dyspareunia From Vulvar Vaginal Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sue Goldstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>San Diego Sexual Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an unblinded study to be conducted at a single research center, San Diego Sexual
      Medicine. Subjects meeting inclusion and exclusion criteria will receive 60 mg ospemifene
      daily for twenty weeks. After the informed consent is signed, a baseline physical
      examination, and vulvoscopy with detailed photography of the vulva, vestibule and vagina,
      will be performed. Physical examination and vulvoscopy with detailed photography of the
      vulva, vestibule and vagina, will be repeated prospectively every 4 weeks for a total of 20
      weeks. Therefore, physical examination and vulvoscopy with detailed photography of the vulva,
      vestibule and vagina will be performed prospectively at baseline (vulvoscopy session 1), 4
      weeks (vulvoscopy session 2), 8 weeks (vulvoscopy session 3), 12, weeks (vulvoscopy session
      4), 16 weeks (vulvoscopy session 5) and 20 weeks (vulvoscopy session 6) following daily
      administration of 60 mg ospemifene.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ospemifene is indicated for post-menopausal women diagnosed with vulvar vaginal atrophy (VVA)
      and dyspareunia. While ospemifene clinically significantly reduces pain associated with
      dyspareunia, there has been little prospective documentation using vulvoscopy with detailed
      photography of the visible changes to the vulva, vestibule and vaginal region with daily
      administration of 60 mg ospemifene in post-menopausal women with VVA and dyspareunia. This
      study will include a total of 6 prospective photographic sessions of the vulva, vestibule and
      vagina over the 20 weeks administration of 60 mg ospemifene in the study. Comparisons will be
      made of baseline photography (vulvoscopy session 0) with photography at 4 weeks (vulvoscopy
      session 1), 8 weeks (vulvoscopy session 2), 12 weeks (vulvoscopy session 3), 16 weeks
      (vulvoscopy session 4) and 20 weeks (vulvoscopy session 5).

      Currently there have been limited prospective studies using vulvoscopy with detailed
      photography demonstrating visible changes to the vulva, vestibule and vagina following oral
      administration of 60 mg ospemifene in post-menopausal women with VVA and dyspareunia.
      Information regarding visible changes to the vulva, vestibule and vagina may be very
      important to the patient and to the health care provider to best understand the beneficial
      effects of ospemifene and to ensure patient compliance with treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">April 17, 2017</completion_date>
  <primary_completion_date type="Actual">February 7, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visible Changes to the Vulva, Vestibule and Vaginal Region on Photography</measure>
    <time_frame>Baseline and 20 weeks</time_frame>
    <description>Change in score on the Vulvoscopic Genital Tissue Appearance (VGTA) scale from baseline to 20 weeks was measured using ten parameters: 1) loss of labia majora, 2) loss of labia minora, 3) decreased glans clitoris, 4) prominence of the urethral meatus, 5) stenosis of the introitus, 6) vestibular pallor, 7) vestibular erythema, 8) loss of vestibular moisture, 9) loss of vaginal rugae, and 10) loss of prominence of the anterior vaginal wall to determine health of the vulva, vestibule and vaginal region using vulvoscopic photographs. VGTA scoring ranges from 0 (normal) to 3 (most severe) for each parameter, for a total score ranging from 0 (normal) to 30 (most severe). Each region assessed is reflected as worse for a higher score and better for a lower score in the 0-3 range, and the same for the total score, with 0 being the best possible score and 30 the worse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Pain Scale</measure>
    <time_frame>Baseline and 20 weeks</time_frame>
    <description>Changes in pain as noted on the pain scale (0-3) by q-tip testing of the vestibule by the clinician, with 0 representing no pain at the location and 3 being severe in each location, 1 o'clock, 3 o'clock, 5 o'clock, 6 o'clock, 7 o'clock, 9 o'clock and 11 o'clock circling the vestibule. The maximum total pain score range is 0 (no pain) to the worst score possible of 21 indicating severe pain at all locations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Sexual Encounters in Which Pain Was Experienced</measure>
    <time_frame>Baseline and 20 weeks</time_frame>
    <description>For each sexual encounter, patients were required to record a ''yes&quot; or &quot;no&quot; response to the following question: Did you experience pain during intercourse? The percentage of sexual encounters in which the woman answered &quot;yes&quot; to this question at baseline (first month of the study) and at week 20 (last month of the study) was compared. The worst score possible was experiencing pain during 100% of sexual encounters and the best possible score was experiencing pain during 0% of sexual encounters at any given assessment period.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Vulvovaginal Atrophy</condition>
  <condition>Dyspareunia</condition>
  <arm_group>
    <arm_group_label>Ospemifene open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg ospemifene daily for 20 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ospemifene</intervention_name>
    <description>FDA approved medication for the treatment of vulvovaginal atrophy and dyspareunia</description>
    <arm_group_label>Ospemifene open label</arm_group_label>
    <other_name>Osphena</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject provides written informed consent and HIPAA authorization before any study
             procedures are conducted

          2. Subject is female

          3. Subject is aged 21-80 years

          4. Subject has a body mass index (BMI) &lt; 37 kg/m2

          5. Subject is menopausal either naturally (at least 12 months amenorrheic) or 6 weeks
             after a bilateral salpingo-oophorectomy prior to natural menopause subjects with
             hysterectomy only must have a serum Follicle Stimulating Hormone &gt; 40
             milli-International unit /mL

          6. Subject has vulvovaginal atrophy with dyspareunia

          7. Subject has had a normal mammogram within the last 6 months

          8. Subject has normal pap smear within last 6 months

          9. Subject has an endometrial stripe â‰¤ 4 mm within the last 6 months if she has a uterus

         10. Subject agrees to comply with the study procedures and visits.

        Exclusion Criteria:

          1. Subject has a hypersensitivity to any of the ingredients of ospemifene

          2. Subject has used ospemifene in the past

          3. Subject has documented or suspected breast cancer, history of heart attack or stroke

          4. Subject has clinically significant findings on physical examination

          5. Subject has uncontrolled hypertension

          6. Subject has any chronic medical condition or psychologic disorder that the Principal
             Investigator feels makes her ineligible for the study

          7. Subject is currently on local or systemic androgen therapy including local or systemic
             testosterone (washout 14 days for local or topical androgen or non-depot injection, 1
             month for depot, 6 months for pellet

          8. Subject is currently on local or systemic estrogen therapy or androgen therapy
             (washout 14 days for vaginal estrogen, 60 days for oral/transdermal therapy)

          9. Subject is currently using a Selective Estrogen Receptor Modulator (SERM) or products
             that have estrogenic or anti-estrogenic effects within last month

         10. Subject currently using itraconazole, ketoconazole, digitalis or alkaloids heparin or
             strong cytochrome P 450 3A4 inhibitors

         11. Subject has a history of substance abuse within 12 months prior, or consuming &gt; 14
             alcoholic drinks per week

         12. Subject has received an investigational drug within 30 days prior to signing consent

         13. Subject has any condition or exhibits behavior that indicates to the Principal
             Investigator that the Subject is unlikely to be compliant with study procedures and
             visits.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irwin Goldstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Diego Sexual Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Diego Sexual Medicine</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bachmann GA, Komi JO; Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010 May-Jun;17(3):480-6. doi: 10.1097/gme.0b013e3181c1ac01.</citation>
    <PMID>20032798</PMID>
  </reference>
  <reference>
    <citation>Portman DJ, Bachmann GA, Simon JA; Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013 Jun;20(6):623-30. doi: 10.1097/gme.0b013e318279ba64.</citation>
    <PMID>23361170</PMID>
  </reference>
  <reference>
    <citation>Goldstein SR, Bachmann GA, Koninckx PR, Lin VH, Portman DJ, Ylikorkala O; Ospemifene Study Group. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric. 2014 Apr;17(2):173-82. doi: 10.3109/13697137.2013.834493. Epub 2013 Nov 23.</citation>
    <PMID>23984673</PMID>
  </reference>
  <reference>
    <citation>Simon JA, Lin VH, Radovich C, Bachmann GA; Ospemifene Study Group. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. 2013 Apr;20(4):418-27. doi: 10.1097/gme.0b013e31826d36ba.</citation>
    <PMID>23096251</PMID>
  </reference>
  <results_reference>
    <citation>Goldstein SW, Winter AG, Goldstein I. Improvements to the Vulva, Vestibule, Urethral Meatus, and Vagina in Women Treated With Ospemifene for Moderate to Severe Dyspareunia: A Prospective Vulvoscopic Pilot Study. Sex Med. 2018 Jun;6(2):154-161. doi: 10.1016/j.esxm.2018.03.002. Epub 2018 Apr 18.</citation>
    <PMID>29678557</PMID>
  </results_reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 20, 2016</study_first_submitted>
  <study_first_submitted_qc>May 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <results_first_submitted>April 20, 2018</results_first_submitted>
  <results_first_submitted_qc>March 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 2, 2019</results_first_posted>
  <last_update_submitted>March 13, 2019</last_update_submitted>
  <last_update_submitted_qc>March 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>San Diego Sexual Medicine</investigator_affiliation>
    <investigator_full_name>Sue Goldstein</investigator_full_name>
    <investigator_title>Clinical Research Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspareunia</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Information will be combined and not reported as individual participant data.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 4, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT02784613/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 4, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT02784613/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT02784613/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ospemifene Open Label</title>
          <description>60 mg ospemifene daily for 20 weeks
Ospemifene: FDA approved medication for the treatment of vulvovaginal atrophy and dyspareunia</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline assessments made for completers only</population>
      <group_list>
        <group group_id="B1">
          <title>Ospemifene Open Label</title>
          <description>60 mg ospemifene daily for 20 weeks
Ospemifene: FDA approved medication for the treatment of vulvovaginal atrophy and dyspareunia</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visible Changes to the Vulva, Vestibule and Vaginal Region on Photography</title>
        <description>Change in score on the Vulvoscopic Genital Tissue Appearance (VGTA) scale from baseline to 20 weeks was measured using ten parameters: 1) loss of labia majora, 2) loss of labia minora, 3) decreased glans clitoris, 4) prominence of the urethral meatus, 5) stenosis of the introitus, 6) vestibular pallor, 7) vestibular erythema, 8) loss of vestibular moisture, 9) loss of vaginal rugae, and 10) loss of prominence of the anterior vaginal wall to determine health of the vulva, vestibule and vaginal region using vulvoscopic photographs. VGTA scoring ranges from 0 (normal) to 3 (most severe) for each parameter, for a total score ranging from 0 (normal) to 30 (most severe). Each region assessed is reflected as worse for a higher score and better for a lower score in the 0-3 range, and the same for the total score, with 0 being the best possible score and 30 the worse.</description>
        <time_frame>Baseline and 20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label</title>
            <description>60 mg ospemifene daily for 20 weeks
Ospemifene: FDA approved medication for the treatment of vulvovaginal atrophy and dyspareunia</description>
          </group>
        </group_list>
        <measure>
          <title>Visible Changes to the Vulva, Vestibule and Vaginal Region on Photography</title>
          <description>Change in score on the Vulvoscopic Genital Tissue Appearance (VGTA) scale from baseline to 20 weeks was measured using ten parameters: 1) loss of labia majora, 2) loss of labia minora, 3) decreased glans clitoris, 4) prominence of the urethral meatus, 5) stenosis of the introitus, 6) vestibular pallor, 7) vestibular erythema, 8) loss of vestibular moisture, 9) loss of vaginal rugae, and 10) loss of prominence of the anterior vaginal wall to determine health of the vulva, vestibule and vaginal region using vulvoscopic photographs. VGTA scoring ranges from 0 (normal) to 3 (most severe) for each parameter, for a total score ranging from 0 (normal) to 30 (most severe). Each region assessed is reflected as worse for a higher score and better for a lower score in the 0-3 range, and the same for the total score, with 0 being the best possible score and 30 the worse.</description>
          <units>points improvement on VGTA scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="7" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>Differences in pre- and post-treatment scores were compared using Wilcoxon signed-rank test for non-parametric matched pairs. All tests of significance were 2-tailed. All analyses were performed in StataÂ®, version 13.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Pain Scale</title>
        <description>Changes in pain as noted on the pain scale (0-3) by q-tip testing of the vestibule by the clinician, with 0 representing no pain at the location and 3 being severe in each location, 1 o'clock, 3 o'clock, 5 o'clock, 6 o'clock, 7 o'clock, 9 o'clock and 11 o'clock circling the vestibule. The maximum total pain score range is 0 (no pain) to the worst score possible of 21 indicating severe pain at all locations.</description>
        <time_frame>Baseline and 20 weeks</time_frame>
        <population>Completers</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label</title>
            <description>60 mg ospemifene daily for 20 weeks
Ospemifene: FDA approved medication for the treatment of vulvovaginal atrophy and dyspareunia</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Pain Scale</title>
          <description>Changes in pain as noted on the pain scale (0-3) by q-tip testing of the vestibule by the clinician, with 0 representing no pain at the location and 3 being severe in each location, 1 o'clock, 3 o'clock, 5 o'clock, 6 o'clock, 7 o'clock, 9 o'clock and 11 o'clock circling the vestibule. The maximum total pain score range is 0 (no pain) to the worst score possible of 21 indicating severe pain at all locations.</description>
          <population>Completers</population>
          <units>points improvement</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="9.5" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Sexual Encounters in Which Pain Was Experienced</title>
        <description>For each sexual encounter, patients were required to record a ''yes&quot; or &quot;no&quot; response to the following question: Did you experience pain during intercourse? The percentage of sexual encounters in which the woman answered &quot;yes&quot; to this question at baseline (first month of the study) and at week 20 (last month of the study) was compared. The worst score possible was experiencing pain during 100% of sexual encounters and the best possible score was experiencing pain during 0% of sexual encounters at any given assessment period.</description>
        <time_frame>Baseline and 20 weeks</time_frame>
        <population>completers</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label</title>
            <description>60 mg ospemifene daily for 20 weeks
Ospemifene: FDA approved medication for the treatment of vulvovaginal atrophy and dyspareunia</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Sexual Encounters in Which Pain Was Experienced</title>
          <description>For each sexual encounter, patients were required to record a ''yes&quot; or &quot;no&quot; response to the following question: Did you experience pain during intercourse? The percentage of sexual encounters in which the woman answered &quot;yes&quot; to this question at baseline (first month of the study) and at week 20 (last month of the study) was compared. The worst score possible was experiencing pain during 100% of sexual encounters and the best possible score was experiencing pain during 0% of sexual encounters at any given assessment period.</description>
          <population>completers</population>
          <units>percentage of sexual encounters</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="20" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months per participant</time_frame>
      <desc>clinical trials dot gov definitions used</desc>
      <group_list>
        <group group_id="E1">
          <title>Open Label</title>
          <description>60 mg ospemifene daily for 20 weeks
Ospemifene: FDA approved medication for the treatment of vulvovaginal atrophy and dyspareunia</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>Caused by medication from sinus infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sinus infection</sub_title>
                <description>medication from sinus infection caused diarrhea for participant</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>microscopic hematuria</sub_title>
                <description>Noted in urine at end of study but no urine sample taken at screening for comparison</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <description>during acute coryza</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>acute coryza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small pilot study size; open label without placebo; reader of vulvoscopic photographs was not involved in any part of data collection or subject visits but was aware of whether the photos were from baseline or end of study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Irwin Goldstein</name_or_title>
      <organization>San Diego Sexual Medicine</organization>
      <phone>619-265-8865</phone>
      <email>dr.irwingoldstein@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

